Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Cardiology›Condition·Updated Jun 3, 2026·v1

Cardiogenic Shock

Cardiogenic shock is a high-mortality syndrome of cardiac-driven hypoperfusion. Management centers on early revascularization, SCAI staging, and a 'Shock Team' approach utilizing invasive hemodynamics and selective mechanical support.

High Evidence191 references·8,251 words·34 min read·v1
CardiologyCritical CareEmergency MedicineMechanical Circulatory Support

Quick Reference

RxDrug of choice[[Norepinephrine]] (vasopressor); [[Dobutamine]] or [[Milrinone]] (inotrope)
AltAlternatives[[Vasopressin]] (for mixed/vasoplegic shock); [[Levosimendan]] (emerging for ECMO weaning)
⊘Avoid[[Dopamine]] (increased arrhythmia/mortality); [[Epinephrine]] (metabolic distress/refractory shock)
DxTest of choiceTransthoracic Echocardiogram (initial); Pulmonary Artery Catheter (gold standard for phenotyping)
ScKey scoreSCAI Shock Staging (A-E)
→When to referImmediate transfer to a Level 1 Shock Center for any patient in SCAI Stage C or higher.
Cardiogenic shock is a medical emergency requiring rapid revascularization, invasive hemodynamic-guided therapy, and early consideration of mechanical support to break the downward spiral of hypoperfusion.
Cardiogenic shock (CS) is a high-acuity clinical syndrome characterized by primary cardiac failure leading to inadequate systemic perfusion and subsequent multiorgan dysfunction. Historically defined by a systolic blood pressure < 90 mmHg, modern management recognizes a spectrum of severity ranging from compensated states (SCAI Stage B) to refractory circulatory collapse (SCAI Stage E). Despite the universal adoption of early revascularization following the landmark SHOCK trial, in-hospital mortality remains high at 40–50%. Management has recently shifted toward early invasive hemodynamic phenotyping using [[pulmonary artery catheterization]], the use of multidisciplinary "Shock Teams," and the selective application of temporary mechanical circulatory support (tMCS), such as microaxial flow pumps, which have recently shown a survival benefit in STEMI-related shock (DanGer Shock trial).

Overview and Recommendations

Background

  • •Cardiogenic shock (CS) represents the extreme end of the acute heart failure spectrum, where a primary cardiac insult—most commonly (AMI)—triggers a self-perpetuating downward spiral of reduced cardiac output, systemic hypotension, and coronary hypoperfusion.
  • •The Society for Cardiovascular Angiography and Interventions (SCAI) staging system (Stages A–E) has replaced binary definitions, providing a dynamic framework that correlates with mortality risk, which ranges from ~3% in Stage A (At Risk) to >67% in Stage E (Extremis).
  • •Ischemic etiologies (AMI-CS) account for the majority of cases, but heart failure-related shock (HF-CS) is increasing in prevalence; notably, the presence of concomitant right ventricular failure occurs in ~11% of patients and independently worsens prognosis across all stages.
  • •Pathophysiology involves not only mechanical pump failure but also a systemic inflammatory response syndrome (SIRS) that can lead to a "mixed shock" phenotype, where low systemic vascular resistance (SVR) complicates the classic "cold and wet" presentation.
  • •The paradigm of management has evolved from the 1999 SHOCK trial (establishing early revascularization) to the 2024 DanGer Shock trial, which provided the first randomized evidence that microaxial flow pumps ( CP) can reduce 180-day mortality in STEMI-related shock (NNT = 8).

Evaluation

  • •Suspect cardiogenic shock in any patient with hypotension (SBP < 90 mmHg or MAP < 65 mmHg) who also exhibits signs of end-organ hypoperfusion, such as altered mental status, cool/mottled extremities, or oliguria (< 0.5 mL/kg/hr).
  • •Perform an immediate bedside (POCUS) to assess left and right ventricular function, rule out mechanical complications (e.g., , acute ), and identify mimics like cardiac tamponade.
  • •Order serial serum levels to quantify the depth of shock; a lactate > 2.0 mmol/L is a hallmark of Stage C shock, and a failure to clear lactate by > 10% within 6 hours of initiation of therapy is a strong predictor of 30-day mortality.
  • •Assess for a narrow pulse pressure (< 25 mmHg), which often precedes overt hypotension in "normotensive" shock variants where high systemic vascular resistance temporarily masks low cardiac output.
  • •Initiate invasive hemodynamic monitoring with a (PAC) to calculate the Cardiac Power Output (CPO = [MAP × CO] / 451); a CPO < 0.6 Watts is the most potent hemodynamic predictor of mortality in CS.
  • •Evaluate right ventricular (RV) reserve using the Pulmonary Artery Pulsatility Index (PAPi = [sPAP - dPAP] / CVP); a PAPi < 1.0 suggests significant RV dysfunction that may require specific right-sided support.
  • •Screen for mechanical complications of MI if a new holosystolic murmur is heard, as these patients require urgent surgical consultation and often benefit from immediate intra-aortic balloon pump (IABP) stabilization.
  • •Differentiate between "cold and wet" (classic CS), "cold and dry" (hypovolemic CS requiring fluid challenge), and "warm and wet" (vasodilatory/mixed shock) phenotypes to tailor vasoactive therapy.

Management

  • •Activate a multidisciplinary "Shock Team" (cardiology, cardiac surgery, critical care) immediately to coordinate rapid revascularization and potential mechanical support escalation.
  • •Prioritize early revascularization in AMI-CS with a target door-to-catheterization (D2C) time of ≤ 39 minutes; use transradial access when possible, as it is associated with a > 50% reduction in mortality compared to femoral access.
  • •Initiate (0.05–0.5 mcg/kg/min) as the first-line vasopressor to maintain a MAP of 65–70 mmHg; avoid due to a higher risk of arrhythmias and mortality.
  • •Add an inotrope, such as (2.5–5 mcg/kg/min) or (0.125–0.25 mcg/kg/min), if signs of low cardiac output persist despite adequate MAP; milrinone may be preferred in patients on chronic beta-blockers.
  • •Avoid as a first-line agent, as it is associated with increased rates of refractory shock and transient lactic acidosis (NNH = 4 for refractory shock).
  • •Consider early insertion of a microaxial flow pump ( CP) in patients with STEMI-related shock (SCAI Stage C or D) to improve 180-day survival, while monitoring closely for major bleeding (BARC 3-5) and hemolysis.
  • •Reserve venoarterial extracorporeal membrane oxygenation ( ) for patients in refractory shock (SCAI Stage E) or those with combined respiratory failure, ensuring proactive left ventricular unloading (e.g., with an IABP or Impella) to prevent pulmonary edema.
  • •Perform culprit-only percutaneous coronary intervention (PCI) in the acute phase of shock for patients with multivessel disease, as immediate multivessel PCI increases the risk of death or renal failure (NNT = 11 to avoid these by choosing culprit-only).
  • •Monitor renal function closely and initiate continuous renal replacement therapy ( ) early if volume overload or metabolic acidosis cannot be managed medically, especially in patients on tMCS.
  • •Transition to guideline-directed medical therapy ( ), including beta-blockers and ACE inhibitors, only after the patient is weaned from all inotropic/vasopressor support and demonstrates hemodynamic stability.

Board Review — High Yield

  • •SCAI Stage C — 'Classic' shock: hypotension + hypoperfusion requiring inotropes or MCS.
  • •Cardiac Power Output (CPO) — (MAP x CO) / 451; < 0.6 Watts is the strongest predictor of mortality.
  • •DanGer Shock Trial — First RCT to show mortality benefit for Impella CP in STEMI-CS (180-day mortality reduction).
  • •CULPRIT-SHOCK Trial — Culprit-only PCI is superior to immediate multivessel PCI in the acute shock setting.
  • •IABP-SHOCK II — Routine use of IABP in AMI-CS does not improve 30-day mortality.
  • •PAPi — (sPAP - dPAP) / CVP; < 1.0 indicates right ventricular failure.
  • •Norepinephrine vs Dopamine — Norepinephrine is superior due to fewer arrhythmic events and lower mortality in CS.
  • •Mechanical Complications — Suspect VSD or papillary muscle rupture if a new murmur develops; IABP is indicated here.

Deep Dive — Evidence Details

References

  1. [1]

    Baran DA, Grines CL, Bailey S et al.. “SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019). PMID: 31104355 ↗

    L1GUIDELINECited in: Definition, Classification, and SCAI Staging, Clinical Presentation and Physical Examination, Guidelines and Management Algorithms
  2. [2]

    Pöss J, Jentzer J, Desch S et al.. “Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial.” ESC heart failure (2025). PMID: 41083288 ↗

    L1RCTCited in: Definition, Classification, and SCAI Staging, Epidemiology and Etiological Spectrum, Temporary Mechanical Circulatory Support (tMCS), Prognostication and Long-term Outcomes
  3. [3]

    Linde L, Beske RP, Meyer MAS et al.. “Hemodynamic Characteristics and Prognostic Implication of Modified Society for Cardiovascular Angiography and Interventions Shock Classification in Comatose Patients With Out-of-Hospital Cardiac Arrest.” Journal of the American Heart Association (2025). PMID: 39704227 ↗

    L3RCTCited in: Definition, Classification, and SCAI Staging
  4. [4]

    Becher T, Hahn L, Britsch M et al.. “Consistency and Risk Stratification Performance of 4 Society for Cardiovascular Angiography and Interventions SHOCK Stage Definitions: A Retrospective Study.” Journal of the American Heart Association (2025). PMID: 40847509 ↗

    L3COHORTCited in: Definition, Classification, and SCAI Staging, Prognostication and Long-term Outcomes
  5. [5]

    van Diepen S, Pöss J, Senaratne JM et al.. “Mixed Cardiogenic Shock: A Proposal for Standardized Classification, a Hemodynamic Definition, and Framework for Management.” Circulation (2024). PMID: 39466889 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification, and SCAI Staging, Pathophysiology and the Hemodynamic Spiral, Clinical Presentation and Physical Examination
  6. [6]

    Hill KL, Rustin MA, Asche MA et al.. “Cardiogenic Shock Classification and Associated Mortality Risk.” Mayo Clinic proceedings (2023). PMID: 37028976 ↗

    L2REVIEW_NARRATIVECited in: Definition, Classification, and SCAI Staging
  7. [7]

    Yuen T, Senaratne JM. “Definition, Classification, and Management of Primary Noncardiac Causes of Cardiogenic Shock.” The Canadian journal of cardiology (2025). PMID: 39675467 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification, and SCAI Staging
  8. [8]

    Britsch S, Britsch M, Hahn L et al.. “Prognostic performance of the SCAI shock classification at admission and during ICU treatment: A retrospective, observational cohort study.” Heart & lung : the journal of critical care (2024). PMID: 38924856 ↗

    L3COHORTCited in: Definition, Classification, and SCAI Staging
  9. [9]

    Dutt DP, Pinney SP. “Clinical variability within the INTERMACS 1 profile: implications for treatment options.” Current opinion in cardiology (2014). PMID: 24694386 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification, and SCAI Staging
  10. [10]

    Jentzer JC, van Diepen S, Barsness GW et al.. “Cardiogenic Shock Classification to Predict Mortality in the Cardiac Intensive Care Unit.” Journal of the American College of Cardiology (2019). PMID: 31548097 ↗

    L3OTHERCited in: Definition, Classification, and SCAI Staging
  11. [11]

    Frea S, Gravinese C, Boretto P et al.. “Comprehensive non-invasive haemodynamic assessment in acute decompensated heart failure-related cardiogenic shock: a step towards echodynamics.” European heart journal. Acute cardiovascular care (2024). PMID: 39012797 ↗

    L2OTHERCited in: Definition, Classification, and SCAI Staging, Diagnostic Workup and Hemodynamic Monitoring
  12. [12]

    Rueda F, Borràs E, García-García C et al.. “Protein-based cardiogenic shock patient classifier.” European heart journal (2019). PMID: 31204432 ↗

    L2OTHERCited in: Definition, Classification, and SCAI Staging
  13. [13]

    Zweck E, Ton VK, Kanwar M et al.. “CSWG-SCAI Stages Combined With Machine Learning-Based Phenotypes for Serial Risk Stratification in Cardiogenic Shock.” JACC. Heart failure (2025). PMID: 40840206 ↗

    L3OTHERCited in: Definition, Classification, and SCAI Staging
  14. [14]

    Jentzer JC, Senghavi D, Patel PC et al.. “Shock Severity Classification and Mortality in Adults With Cardiac, Medical, Surgical, and Neurological Critical Illness.” Mayo Clinic proceedings (2024). PMID: 37815781 ↗

    L3OTHERCited in: Definition, Classification, and SCAI Staging
  15. [15]

    Jentzer JC, Baran DA, Kyle Bohman J et al.. “Cardiogenic shock severity and mortality in patients receiving venoarterial extracorporeal membrane oxygenator support.” European heart journal. Acute cardiovascular care (2022). PMID: 36173885 ↗

    L3OTHERCited in: Definition, Classification, and SCAI Staging
  16. [16]

    Baran DA, Long A, Badiye AP et al.. “Prospective validation of the SCAI shock classification: Single center analysis.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020). PMID: 33026155 ↗

    L2OTHERCited in: Definition, Classification, and SCAI Staging
  17. [17]

    Scott M, Kyriakopoulos CP, Sheffield E et al.. “Application of the Updated Cardiogenic Shock Working Group SCAI Classification for Cardiogenic Shock: A Single-Centre Analysis.” The Canadian journal of cardiology (2025). PMID: 40311672 ↗

    L3OTHERCited in: Definition, Classification, and SCAI Staging
  18. [18]

    Sarma D, Tabi M, Jentzer JC. “Society for cardiovascular angiography and intervention shock classification predicts mortality after out-of-hospital cardiac arrest.” Resuscitation (2022). PMID: 35122891 ↗

    L3OTHERCited in: Definition, Classification, and SCAI Staging
  19. [19]

    Morici N, Frea S, Bertaina M et al.. “SCAI stage reclassification at 24 h predicts outcome of cardiogenic shock: Insights from the Altshock-2 registry.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2023). PMID: 36378673 ↗

    L2OTHERCited in: Definition, Classification, and SCAI Staging
  20. [20]

    Oyabu K, Hattori H, Kikuchi N et al.. “Cardiogenic shock severity predicts bleeding events in patients with temporary mechanical circulatory support.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2024). PMID: 39219443 ↗

    L3OTHERCited in: Definition, Classification, and SCAI Staging
  21. [21]

    Obradovic D, Schulz L, Loncar G et al.. “Prognostic performance of cardiogenic shock 4 proteins prediction model in infarct-related cardiogenic shock.” ESC heart failure (2026). PMID: 41711227 ↗

    L2RCTCited in: Epidemiology and Etiological Spectrum, Prognostication and Long-term Outcomes
  22. [22]

    Sørensen R, Møller JE, Vandenbriele C et al.. “Bleeding in Patients With Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.” JACC. Cardiovascular interventions (2026). PMID: 41672689 ↗

    L1RCTCited in: Epidemiology and Etiological Spectrum, Temporary Mechanical Circulatory Support (tMCS), Prognostication and Long-term Outcomes
  23. [23]

    Armstrong PW, Zheng Y, Welsh RC et al.. “Primary percutaneous coronary intervention within the first hour: Insights from early-treated patients with ST-elevation myocardial infarction.” American heart journal (2026). PMID: 41619999 ↗

    L1RCTCited in: Epidemiology and Etiological Spectrum
  24. [24]

    Combes A, Saura O, Nesseler N et al.. “Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial.” JAMA (2026). PMID: 41324946 ↗

    L1RCTCited in: Epidemiology and Etiological Spectrum, Temporary Mechanical Circulatory Support (tMCS), Multiorgan Dysfunction and Supportive Care
  25. [25]

    Thevathasan T, Alyahoud M, Freund A et al.. “Extracorporeal Membrane Oxygenation Complications Are Not Causal for Mortality in Patients With Infarct-Related Cardiogenic Shock: A Mediation Analysis of the Extracorporeal Life Support in Infarct-Related Cardiogenic Shock (ECLS-SHOCK) Trial.” Critical care medicine (2025). PMID: 41114622 ↗

    L1RCTCited in: Epidemiology and Etiological Spectrum, Temporary Mechanical Circulatory Support (tMCS)
  26. [26]

    Pagnesi M, Cotter G, Davison B et al.. “Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial.” ESC heart failure (2025). PMID: 41085472 ↗

    L1RCTCited in: Epidemiology and Etiological Spectrum
  27. [27]

    Haberman D, Verma B, Abusnina W et al.. “Low- Versus High-capacity Impella for CS After AMI: A Systematic Review and Pooled Data Analysis.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41507087 ↗

    L1SR_OBSCited in: Epidemiology and Etiological Spectrum, Temporary Mechanical Circulatory Support (tMCS), Revascularization and Definitive Interventions
  28. [28]

    Parlow S, Jung RG, Almoosawy SA et al.. “Prognostic Factors Among Patients Receiving Microaxial Flow Pump for Acute Myocardial Infarction-Related Cardiogenic Shock: A Systematic Review and Meta-Analysis.” Critical care medicine (2026). PMID: 41504526 ↗

    L1SR_OBSCited in: Epidemiology and Etiological Spectrum
  29. [29]

    Scquizzato T, Grunau B, Fernando SM et al.. “Temporary mechanical circulatory support after return of spontaneous circulation following cardiac arrest: a systematic review and meta-analysis.” Resuscitation (2025). PMID: 41232590 ↗

    L1SR_OBSCited in: Epidemiology and Etiological Spectrum, Temporary Mechanical Circulatory Support (tMCS)
  30. [30]

    Ng GWY, Low CJW, Ng KJ et al.. “Predictive Models for Mortality in Cardiogenic Shock: A Systematic Review and Meta-Analysis.” Critical care medicine (2026). PMID: 41212048 ↗

    L1SR_OBSCited in: Epidemiology and Etiological Spectrum, Prognostication and Long-term Outcomes
  31. [31]

    Sans-Roselló J, Fernández-Peregrina E, Kuku KO et al.. “Timing of cardiogenic shock and clinical outcomes in takotsubo syndrome: A multicenter cohort study.” International journal of cardiology (2026). PMID: 41765143 ↗

    L3COHORTCited in: Epidemiology and Etiological Spectrum
  32. [32]

    Yokawa J, Nishikawa T, Shimojima M et al.. “Early initiation of guideline-directed medical therapy in patients with cardiogenic shock supported with Impella®: a two-center retrospective study.” BMC cardiovascular disorders (2025). PMID: 41257682 ↗

    L3COHORTCited in: Epidemiology and Etiological Spectrum, Temporary Mechanical Circulatory Support (tMCS), Prognostication and Long-term Outcomes
  33. [33]

    Hyder SA, Shirwany H, Parcha V et al.. “Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort Study.” The American journal of cardiology (2026). PMID: 41253240 ↗

    L3COHORTCited in: Epidemiology and Etiological Spectrum, Temporary Mechanical Circulatory Support (tMCS)
  34. [34]

    Sheng Z, Chen B. “Differences in the characteristics and outcomes of STEMI versus NSTEMI cardiogenic shock: A systematic review and meta-analysis.” Medicine (2025). PMID: 41189239 ↗

    L2SR_OBSCited in: Epidemiology and Etiological Spectrum
  35. [35]

    Besnard A, Djebbar M, Akodad M et al.. “Emergency Mitral Transcatheter Edge-to-Edge Repair as a Bridge to Surgical Mitral Valve Replacement in Cardiogenic Shock: A Case Report.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41881834 ↗

    L4CASE_REPORTCited in: Epidemiology and Etiological Spectrum, Diagnostic Workup and Hemodynamic Monitoring
  36. [36]

    Zhang Y, Li R, Jiang Y et al.. “Successful ECMO support for cardiogenic shock induced by immune checkpoint inhibitor-associated myocarditis: a case report and literature review.” Frontiers in immunology (2025). PMID: 41438754 ↗

    L4CASE_REPORTCited in: Epidemiology and Etiological Spectrum, Temporary Mechanical Circulatory Support (tMCS)
  37. [37]

    Pesce F, Dini CS, Righini FM et al.. “Optimizing cardiogenic shock outcomes: A system-based network approach.” International journal of cardiology (2026). PMID: 42082006 ↗

    L2OTHERCited in: Epidemiology and Etiological Spectrum
  38. [38]

    Adi A, Jain R, Guru S et al.. “Antimicrobial Use in Acute Myocardial Infarction-Related Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 41904804 ↗

    L3OTHERCited in: Epidemiology and Etiological Spectrum
  39. [39]

    Suzuki T, Asano T, Shinozaki T et al.. “Prognostic Implications of Bleeding and Ischemic Complications in Acute Myocardial Infarction-Related Cardiogenic Shock Managed With Microaxial Flow Pump.” Circulation. Cardiovascular interventions (2026). PMID: 41904791 ↗

    L3OTHERCited in: Epidemiology and Etiological Spectrum
  40. [40]

    Lapetina Arroyo R, Khosla P, Caraballo C et al.. “Impact of right heart failure in patients with cardiogenic shock.” European heart journal. Acute cardiovascular care (2026). PMID: 41863824 ↗

    L3OTHERCited in: Epidemiology and Etiological Spectrum
  41. [41]

    Pfeffer TJ, Matinmehr F, Radocaj A et al.. “Cardiogenic shock complicating peripartum cardiomyopathy benefits from combination therapy with levosimendan and bromocriptine.” European journal of heart failure (2026). PMID: 41771115 ↗

    L5OTHERCited in: Epidemiology and Etiological Spectrum
  42. [42]

    Wybraniec MT, Sufryd A, Cichoń M et al.. “Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.” ESC heart failure (2026). PMID: 41746839 ↗

    L3OTHERCited in: Epidemiology and Etiological Spectrum, Temporary Mechanical Circulatory Support (tMCS), Revascularization and Definitive Interventions
  43. [43]

    Elhadad A, El Zouhayri O, Silvain J et al.. “Efficacy and Safety of Intravenous Antiplatelet Therapy in Acute Myocardial Infarction With Cardiogenic Shock.” JACC. Cardiovascular interventions (2026). PMID: 41672691 ↗

    L3OTHERCited in: Epidemiology and Etiological Spectrum, Revascularization and Definitive Interventions
  44. [44]

    Fernandez J, Khan N, Rubens M et al.. “Incidence and In-Hospital Mortality of Ventricular Septal Rupture Following Acute Myocardial Infarction.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41656944 ↗

    L2OTHERCited in: Epidemiology and Etiological Spectrum
  45. [45]

    Møller JE, Beske RP, Jensen LO et al.. “Effect of Microaxial Flow Pump on Hemodynamics in STEMI-Related Cardiogenic Shock.” Journal of the American College of Cardiology (2025). PMID: 40562510 ↗

    L1RCTCited in: Pathophysiology and the Hemodynamic Spiral
  46. [46]

    Biegus J, Mebazaa A, Metra M et al.. “Safety and efficacy intravenous istaroxime up to 60 hours for patients with pre-cardiogenic shock.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2025). PMID: 40451596 ↗

    L1RCTCited in: Pathophysiology and the Hemodynamic Spiral
  47. [47]

    Fukushima N, Tatsumi E, Seguchi O et al.. “Assessment of Safety and Effectiveness of the Extracorporeal Continuous-Flow Ventricular Assist Device (BR16010) Use as a Bridge-to-Decision Therapy for Severe Heart Failure or Refractory Cardiogenic Shock: Study Protocol for Single-Arm Non-randomized, Uncontrolled, and Investigator-Initiated Clinical Trial.” Cardiovascular drugs and therapy (2018). PMID: 29948739 ↗

    L5TRIAL_NONRANDOMCited in: Pathophysiology and the Hemodynamic Spiral
  48. [48]

    Spaeth LD, Rahim M, Kochar A et al.. “Cardiogenic Shock and Temporary Mechanical Circulatory Support.” The Medical clinics of North America (2025). PMID: 41136064 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral, Temporary Mechanical Circulatory Support (tMCS)
  49. [49]

    Théry G, Aissaoui N, Hamzaoui O. “Cardiac and systemic inflammation in cardiogenic shock.” Current opinion in critical care (2025). PMID: 40522922 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  50. [50]

    Krause TT, Werner N, Leick J. “Microaxial flow-pump support in patients with cardiogenic shock: a review of the literature.” Current opinion in critical care (2025). PMID: 40522088 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  51. [51]

    Germinario L, Catena D, Ott S et al.. “Iron deficiency in patients with cardiogenic shock: protocol for a scoping review.” BMJ open (2025). PMID: 40254303 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  52. [52]

    Randhawa VK, Baran DA, Kanwar MK et al.. “The Comparative Epidemiology, Pathophysiology and Management of Cardiogenic Shock Associated With Acute Myocardial Infarction and Advanced Heart Failure.” The Canadian journal of cardiology (2025). PMID: 39892612 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  53. [53]

    Moller JE, Thiele H, Zeymer U et al.. “Mechanical circulatory support for patients with infarct-related cardiogenic shock: a state-of-the-art review.” Heart (British Cardiac Society) (2025). PMID: 39819613 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  54. [54]

    Sideris K, Kyriakopoulos CP, Brinker L et al.. “Advanced Markers for Hemodynamic Monitoring in Cardiogenic Shock and End-Stage Heart Failure: A Mini Review.” Heart failure reviews (2025). PMID: 39808367 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  55. [55]

    Brahmbhatt DH, Kalra S, Luk A et al.. “From Escalate to Elevate: A New Paradigm for Comprehensive Cardiogenic Shock Management.” The Canadian journal of cardiology (2025). PMID: 39798668 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  56. [56]

    Maigrot JA, Wakefield BJ, Donaldson CM et al.. “Tailored Approach to Temporary Mechanical Circulatory Support for Cardiogenic Shock: Strategies to Facilitate Patient Mobilization.” Current cardiology reports (2025). PMID: 39792281 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  57. [57]

    Schemmelmann M, Kelm M, Jung C. “The microcirculation in cardiogenic shock.” European heart journal. Acute cardiovascular care (2024). PMID: 39506546 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  58. [58]

    Besch L, Schrage B. “Unloading in cardiogenic shock: the rationale and current evidence.” Current opinion in critical care (2024). PMID: 38841993 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  59. [59]

    Ostadal P, Belohlavek J. “What is cardiogenic shock? New clinical criteria urgently needed.” Current opinion in critical care (2024). PMID: 38841985 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral, Clinical Presentation and Physical Examination
  60. [60]

    Tehrani BN, Truesdell AG, Psotka MA et al.. “A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock.” JACC. Heart failure (2020). PMID: 33121700 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  61. [61]

    Squara P, Hollenberg S, Payen D. “Reconsidering Vasopressors for Cardiogenic Shock: Everything Should Be Made as Simple as Possible, but Not Simpler.” Chest (2019). PMID: 30935893 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  62. [62]

    Chakravarthy M, Tsukashita M, Murali S. “A Targeted Management Approach to Cardiogenic Shock.” Critical care clinics (2018). PMID: 29907274 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and the Hemodynamic Spiral
  63. [63]

    Uribarri A, Guillen-Del Castillo A, Belahnech Y et al.. “Cardiogenic shock in systemic sclerosis: a retrospective study of acute ventricular dysfunction.” Rheumatology international (2025). PMID: 40285931 ↗

    L4COHORTCited in: Pathophysiology and the Hemodynamic Spiral
  64. [64]

    Jacquot A, Lepage X, Merckle L et al.. “Protocol for a multicentre randomised controlled trial evaluating the effects of moderate hypothermia versus normothermia on mortality in patients with refractory cardiogenic shock rescued by venoarterial extracorporeal membrane oxygenation (VA-ECMO) (HYPO-ECMO study).” BMJ open (2019). PMID: 31615800 ↗

    L5TRIAL_NONRANDOMCited in: Clinical Presentation and Physical Examination
  65. [65]

    Lim HS, Vondrakova D, Belohlavek J et al.. “Diastolic Perfusion Pressure Predicts Response to Inotropes and Vasopressors and Benefit From Mechanical Circulatory Support in Cardiogenic Shock.” Circulation. Heart failure (2025). PMID: 40365681 ↗

    L2RCTCited in: Clinical Presentation and Physical Examination
  66. [66]

    Takagi K, Blet A, Levy B et al.. “Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial.” European journal of heart failure (2020). PMID: 31472039 ↗

    L2RCTCited in: Clinical Presentation and Physical Examination
  67. [67]

    Mhanna M, Al-Abdouh A, Sauer MC et al.. “Hypothermia as an Adjunctive Therapy in Cardiogenic Shock: A Systematic Review and Meta-Analysis.” Therapeutic hypothermia and temperature management (2023). PMID: 37074118 ↗

    L1SR_OBSCited in: Clinical Presentation and Physical Examination, Multiorgan Dysfunction and Supportive Care
  68. [68]

    Werdan K, Buerke M, Geppert A et al.. “Infarction-Related Cardiogenic Shock- Diagnosis, Monitoring and Therapy–A German-Austrian S3 Guideline.” Deutsches Arzteblatt international (2021). PMID: 33827749 ↗

    L1GUIDELINECited in: Clinical Presentation and Physical Examination
  69. [69]

    Shaffer A, Sheikh O, Prasad A. “Cardiogenic Shock: A Systematic Review of Clinical Trials Registered With ClinicalTrials.gov.” The Journal of invasive cardiology (2020). PMID: 32240097 ↗

    L5TRIAL_NONRANDOMCited in: Clinical Presentation and Physical Examination
  70. [70]

    You X, Zhu Y, Zhang Z et al.. “Blood Pressure Response Index and Mortality in Patients With Cardiogenic Shock: A Multicenter Retrospective Cohort Study.” Journal of the American Heart Association (2025). PMID: 40879024 ↗

    L3COHORTCited in: Clinical Presentation and Physical Examination, Prognostication and Long-term Outcomes
  71. [71]

    Es-Saad O, Ng W, Messina A et al.. “Current perspectives in cardiogenic shock.” Journal of critical care (2026). PMID: 41655405 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation and Physical Examination, Diagnostic Workup and Hemodynamic Monitoring, Temporary Mechanical Circulatory Support (tMCS)
  72. [72]

    Møller JE, Hassager C, Proudfoot A et al.. “Cardiogenic shock: diagnosis, phenotyping and management.” Intensive care medicine (2025). PMID: 40768067 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation and Physical Examination
  73. [73]

    Galusko V, Wenzl FA, Vandenbriele C et al.. “Current and novel biomarkers in cardiogenic shock.” European journal of heart failure (2025). PMID: 39822053 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation and Physical Examination
  74. [74]

    Damluji AA, Tehrani B, Sinha SS et al.. “Position Statement on Vascular Access Safety for Percutaneous Devices in AMI Complicated by Cardiogenic Shock.” JACC. Cardiovascular interventions (2022). PMID: 36265932 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation and Physical Examination
  75. [75]

    Sciaccaluga C, Mandoli GE, Ghionzoli N et al.. “Risk stratification in cardiogenic shock: a focus on the available evidence.” Heart failure reviews (2022). PMID: 34263413 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation and Physical Examination
  76. [76]

    Lashin H, Olusanya O, Smith A et al.. “Right ventricular echocardiographic parameters and prediction of stroke volume in ischemic cardiogenic shock: A retrospective study.” Journal of critical care (2023). PMID: 36494258 ↗

    L3COHORTCited in: Diagnostic Workup and Hemodynamic Monitoring
  77. [77]

    Xu Q, Wang J, Lin Z et al.. “The glycemic gap as a prognostic indicator in cardiogenic shock: a retrospective cohort study.” BMC cardiovascular disorders (2024). PMID: 39223451 ↗

    L3COHORTCited in: Diagnostic Workup and Hemodynamic Monitoring
  78. [78]

    Scolari FL, Schneider D, Fogazzi DV et al.. “Association between serum lactate levels and mortality in patients with cardiogenic shock receiving mechanical circulatory support: a multicenter retrospective cohort study.” BMC cardiovascular disorders (2020). PMID: 33234107 ↗

    L3COHORTCited in: Diagnostic Workup and Hemodynamic Monitoring
  79. [79]

    Anderson J, Rushton WF, Burleson SL et al.. “Calcium channel antagonists and point-of-care ultrasound: A case series.” The American journal of emergency medicine (2026). PMID: 41349276 ↗

    L4CASE_REPORTCited in: Diagnostic Workup and Hemodynamic Monitoring, Temporary Mechanical Circulatory Support (tMCS)
  80. [80]

    Licciardi M, Sanna F, Melis M et al.. “Transcatheter Edge to Edge Repair as a Bridge to Recovery in Patient With Severe Mitral Regurgitation, Advanced Left Ventricular Dysfunction and ECMO Support: A Case Report.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40421705 ↗

    L4CASE_REPORTCited in: Diagnostic Workup and Hemodynamic Monitoring
  81. [81]

    Lochy S, Galloo X, Droogmans S et al.. “Paravalvular leak closure of a native aortic valve for cardiogenic shock post valvular surgery.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2024). PMID: 38971970 ↗

    L4CASE_REPORTCited in: Diagnostic Workup and Hemodynamic Monitoring
  82. [82]

    Blusztein D, Teng P, Deuse T et al.. “Shock, Thrombus, TAVR: A Challenging TAVR With Large Left-Ventricular Thrombus.” The Canadian journal of cardiology (2021). PMID: 34139300 ↗

    L4CASE_REPORTCited in: Diagnostic Workup and Hemodynamic Monitoring
  83. [83]

    Garau G, Joachim S, Duliere GL et al.. “Sudden cardiogenic shock mimicking fulminant myocarditis in a surviving teenager affected by severe acute respiratory syndrome coronavirus 2 infection.” ESC heart failure (2021). PMID: 33190387 ↗

    L4CASE_REPORTCited in: Diagnostic Workup and Hemodynamic Monitoring
  84. [84]

    Sharif S, Wang K, Basmaji J et al.. “Critical Care Ultrasonography for Cardiogenic Shock: A Scoping Review.” Critical care explorations (2026). PMID: 41817314 ↗

    L5REVIEW_NARRATIVECited in: Diagnostic Workup and Hemodynamic Monitoring
  85. [85]

    Saura O, Hekimian G, Schmidt M. “Echography monitoring in patients with temporary mechanical circulatory support.” Current opinion in critical care (2025). PMID: 40079507 ↗

    L5REVIEW_NARRATIVECited in: Diagnostic Workup and Hemodynamic Monitoring
  86. [86]

    Sacchi S, Venuti A, Gobbi FM et al.. “Clinical Prediction Score for Successful Liberation from Temporary Mechanical Circulatory Support in Cardiogenic Shock Patients.” The Canadian journal of cardiology (2025). PMID: 39947458 ↗

    L3OTHERCited in: Diagnostic Workup and Hemodynamic Monitoring
  87. [87]

    Wang X, Fan X, Wu T et al.. “A CLINICAL PREDICTION MODEL FOR SHORT-TERM PROGNOSIS IN PATIENTS WITH NON-ACUTE MYOCARDIAL INFARCTION-RELATED CARDIOGENIC SHOCK.” Shock (Augusta, Ga.) (2025). PMID: 39665474 ↗

    L2OTHERCited in: Diagnostic Workup and Hemodynamic Monitoring
  88. [88]

    Berg-Hansen K, Ito S, Oh J et al.. “Global longitudinal strain is a predictor of mortality in patients with cardiogenic shock.” European heart journal. Cardiovascular Imaging (2025). PMID: 39657586 ↗

    L3OTHERCited in: Diagnostic Workup and Hemodynamic Monitoring
  89. [89]

    Tavazzi G, Colombo CNJ, Klersy C et al.. “Echocardiographic parameters for weaning from extracorporeal membrane oxygenation-the role of longitudinal function and cardiac time intervals.” European heart journal. Cardiovascular Imaging (2025). PMID: 39441992 ↗

    L2OTHERCited in: Diagnostic Workup and Hemodynamic Monitoring
  90. [90]

    Sato K, Heinsar S, Chan J et al.. “A novel echocardiographic parameter considering left ventricular afterload during V-A ECMO support.” European journal of clinical investigation (2024). PMID: 38849326 ↗

    L5OTHERCited in: Diagnostic Workup and Hemodynamic Monitoring
  91. [91]

    Tavazzi G, Corradi F, Vandenbriele C et al.. “Multimodality imaging in cardiogenic shock: state-of-the art.” Current opinion in critical care (2023). PMID: 37395328 ↗

    L5REVIEW_NARRATIVECited in: Diagnostic Workup and Hemodynamic Monitoring
  92. [92]

    Harrington J, Aron J, Lashin H. “The Role of Focused 2-Dimensional Echocardiography in Managing Left Ventricular Outflow Tract Obstruction Mimicking Cardiogenic Shock.” Journal of intensive care medicine (2023). PMID: 37287244 ↗

    L4REVIEW_NARRATIVECited in: Diagnostic Workup and Hemodynamic Monitoring
  93. [93]

    Singam NSV, Tabi M, Wiley B et al.. “Echocardiographic findings in cardiogenic shock due to acute myocardial infarction versus heart failure.” International journal of cardiology (2023). PMID: 37116757 ↗

    L3OTHERCited in: Diagnostic Workup and Hemodynamic Monitoring
  94. [94]

    Murphy A, Goldberg S. “Mechanical Complications of Myocardial Infarction.” The American journal of medicine (2022). PMID: 36075485 ↗

    L5REVIEW_NARRATIVECited in: Diagnostic Workup and Hemodynamic Monitoring
  95. [95]

    Ramadan A, Abdallah T, Abdelsalam H et al.. “Accuracy of echocardiography and ultrasound protocol to identify shock etiology in emergency department.” BMC emergency medicine (2022). PMID: 35768775 ↗

    L2OTHERCited in: Diagnostic Workup and Hemodynamic Monitoring
  96. [96]

    Tabi M, Singam NSV, Wiley B et al.. “Echocardiographic Characteristics of Cardiogenic Shock Patients with and Without Cardiac Arrest.” Journal of intensive care medicine (2023). PMID: 35656768 ↗

    L3OTHERCited in: Diagnostic Workup and Hemodynamic Monitoring
  97. [97]

    Jentzer JC, Tabi M, Wiley BM et al.. “Echocardiographic Correlates of Mortality Among Cardiac Intensive Care Unit Patients With Cardiogenic Shock.” Shock (Augusta, Ga.) (2022). PMID: 34710882 ↗

    L3OTHERCited in: Diagnostic Workup and Hemodynamic Monitoring
  98. [98]

    VanDyck TJ, Pinsky MR. “Hemodynamic monitoring in cardiogenic shock.” Current opinion in critical care (2021). PMID: 33967209 ↗

    L5REVIEW_NARRATIVECited in: Diagnostic Workup and Hemodynamic Monitoring
  99. [99]

    Kim D, Jang WJ, Park TK et al.. “Echocardiographic Predictors of Successful Extracorporeal Membrane Oxygenation Weaning After Refractory Cardiogenic Shock.” Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography (2021). PMID: 33321165 ↗

    L3OTHERCited in: Diagnostic Workup and Hemodynamic Monitoring
  100. [100]

    Daly M, Long B, Koyfman A et al.. “Identifying cardiogenic shock in the emergency department.” The American journal of emergency medicine (2020). PMID: 33039227 ↗

    L5REVIEW_NARRATIVECited in: Diagnostic Workup and Hemodynamic Monitoring
  101. [101]

    Chiu MH, Howlett JG, Sharma NC. “Initiation of ivabradine in cardiogenic shock.” ESC heart failure (2019). PMID: 31332966 ↗

    L5OTHERCited in: Diagnostic Workup and Hemodynamic Monitoring
  102. [102]

    Pandompatam G, Goswami R. “Noninvasive Echocardiographic Hemodynamics in Patients on Mechanical Circulatory Support: A Case Series.” ASAIO journal (American Society for Artificial Internal Organs : 1992) (2026). PMID: 40934345 ↗

    L4CASE_REPORTCited in: Diagnostic Workup and Hemodynamic Monitoring
  103. [103]

    Marbach JA, Di Santo P, Kapur NK et al.. “Lactate Clearance as a Surrogate for Mortality in Cardiogenic Shock: Insights From the DOREMI Trial.” Journal of the American Heart Association (2022). PMID: 35261289 ↗

    L2RCTCited in: Pharmacological Management: Inotropes and Vasopressors
  104. [104]

    Parlow S, Di Santo P, Mathew R et al.. “The association between mean arterial pressure and outcomes in patients with cardiogenic shock: insights from the DOREMI trial.” European heart journal. Acute cardiovascular care (2021). PMID: 34382063 ↗

    L2RCTCited in: Pharmacological Management: Inotropes and Vasopressors
  105. [105]

    Di Santo P, Mathew R, Jung RG et al.. “Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial.” Critical care (London, England) (2021). PMID: 34376218 ↗

    L2RCTCited in: Pharmacological Management: Inotropes and Vasopressors
  106. [106]

    Mathew R, Di Santo P, Jung RG et al.. “Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.” The New England journal of medicine (2021). PMID: 34347952 ↗

    L1RCTCited in: Pharmacological Management: Inotropes and Vasopressors
  107. [107]

    Levy B, Clere-Jehl R, Legras A et al.. “Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction.” Journal of the American College of Cardiology (2018). PMID: 29976291 ↗

    L1RCTCited in: Pharmacological Management: Inotropes and Vasopressors
  108. [108]

    Lawson CK, Faine BA, Rech MA et al.. “Norepinephrine versus epinephrine for hemodynamic support in post-cardiac arrest shock: A systematic review.” The American journal of emergency medicine (2024). PMID: 38150986 ↗

    L2SR_OBSCited in: Pharmacological Management: Inotropes and Vasopressors
  109. [109]

    Léopold V, Gayat E, Pirracchio R et al.. “Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients.” Intensive care medicine (2018). PMID: 29858926 ↗

    L2SR_OBSCited in: Pharmacological Management: Inotropes and Vasopressors
  110. [110]

    Skoog CA, Engebretsen KM. “Are vasopressors useful in toxin-induced cardiogenic shock?” Clinical toxicology (Philadelphia, Pa.) (2017). PMID: 28152638 ↗

    L1SR_OBSCited in: Pharmacological Management: Inotropes and Vasopressors
  111. [111]

    Liao X, Qian L, Zhang S et al.. “Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.” Journal of healthcare engineering (2020). PMID: 32802302 ↗

    L1SR_OBSCited in: Pharmacological Management: Inotropes and Vasopressors
  112. [112]

    Bloom JE, Ball J, Okyere D et al.. “Design and rationale of a multicenter paramedic randomized trial of noradrenaline versus adrenaline in the initial management of patients with cardiogenic shock-The PANDA trial.” American heart journal (2026). PMID: 41679570 ↗

    L5TRIAL_NONRANDOMCited in: Pharmacological Management: Inotropes and Vasopressors
  113. [113]

    Parlow S, Santo PD, Sterling LH et al.. “Inotrope versus placebo therapy in cardiogenic shock: Rationale and study design of the CAPITAL DOREMI2 trial.” American heart journal (2023). PMID: 37094667 ↗

    L5TRIAL_NONRANDOMCited in: Pharmacological Management: Inotropes and Vasopressors
  114. [114]

    Perez P, Kimmoun A, Blime V et al.. “Increasing mean arterial pressure in cardiogenic shock secondary to myocardial infarction: effects on hemodynamics and tissue oxygenation.” Shock (Augusta, Ga.) (2014). PMID: 24509521 ↗

    L4TRIAL_NONRANDOMCited in: Pharmacological Management: Inotropes and Vasopressors
  115. [115]

    Rui Q, Jiang Y, Chen M et al.. “Dopamine versus norepinephrine in the treatment of cardiogenic shock: A PRISMA-compliant meta-analysis.” Medicine (2017). PMID: 29069037 ↗

    L1SR_OBSCited in: Pharmacological Management: Inotropes and Vasopressors
  116. [116]

    Beyls C, Hanquiez T, Mollet N et al.. “The Effect of Vasopressin on 90-Day Mortality in Patients With Cardiogenic Shock: A Retrospective Cohort Study Using Propensity Score-Weighted Analysis.” Cardiovascular therapeutics (2025). PMID: 40469854 ↗

    L3COHORTCited in: Pharmacological Management: Inotropes and Vasopressors, Prognostication and Long-term Outcomes
  117. [117]

    Biswas S, Malik AH, Bandyopadhyay D et al.. “Meta-analysis Comparing the Efficacy of Dobutamine Versus Milrinone in Acute Decompensated Heart Failure and Cardiogenic Shock.” Current problems in cardiology (2023). PMID: 35545181 ↗

    L1SR_OBSCited in: Pharmacological Management: Inotropes and Vasopressors
  118. [118]

    Uhlig K, Efremov L, Tongers J et al.. “Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.” The Cochrane database of systematic reviews (2020). PMID: 33152122 ↗

    L1SR_OBSCited in: Pharmacological Management: Inotropes and Vasopressors
  119. [119]

    Schumann J, Henrich EC, Strobl H et al.. “Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.” The Cochrane database of systematic reviews (2018). PMID: 29376560 ↗

    L1SR_OBSCited in: Pharmacological Management: Inotropes and Vasopressors
  120. [120]

    Unverzagt S, Wachsmuth L, Hirsch K et al.. “Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome.” The Cochrane database of systematic reviews (2014). PMID: 24385385 ↗

    L1SR_OBSCited in: Pharmacological Management: Inotropes and Vasopressors
  121. [121]

    Guinot PG, Nguyen M, Berthoud V et al.. “Timing of vasopressin initiation influences renal outcomes in mixed cardiogenic-vasodilatory shock supported by VA-ECMO.” Anaesthesia, critical care & pain medicine (2026). PMID: 41207377 ↗

    L3OTHERCited in: Pharmacological Management: Inotropes and Vasopressors
  122. [122]

    Manoeuvrier F, Recher M, Grimaud M et al.. “Use of milrinone in pediatric intensive care units: a multicenter survey of French-speaking countries.” European journal of pediatrics (2025). PMID: 41186722 ↗

    L5OTHERCited in: Pharmacological Management: Inotropes and Vasopressors
  123. [123]

    Patel SM, Berg DD, Bohula EA et al.. “Contemporary Practice Patterns of Vasoactive Use in Cardiogenic Shock in the American Heart Association Cardiogenic Shock Registry.” Journal of the American Heart Association (2025). PMID: 41147380 ↗

    L2OTHERCited in: Pharmacological Management: Inotropes and Vasopressors
  124. [124]

    Li B, Gershengorn HB, Vail EA et al.. “Inotrope selection in mixed cardiogenic shock with sepsis: a comparative analysis between milrinone and dobutamine.” Annals of the American Thoracic Society (2026). PMID: 40960311 ↗

    L2OTHERCited in: Pharmacological Management: Inotropes and Vasopressors
  125. [125]

    Ten Berg S, Bogerd M, Peters EJ et al.. “Milrinone versus dobutamine in acute myocardial infarction-related cardiogenic shock; a propensity score matched analysis.” Clinical research in cardiology : official journal of the German Cardiac Society (2025). PMID: 40900181 ↗

    L2OTHERCited in: Pharmacological Management: Inotropes and Vasopressors
  126. [126]

    Sarma D, Smith R, Padkins M et al.. “Association between vasopressin administration and mortality in patients with cardiogenic shock.” American heart journal (2025). PMID: 40120706 ↗

    L3OTHERCited in: Pharmacological Management: Inotropes and Vasopressors
  127. [127]

    Ortega-Hernández JA, González-Pacheco H, García-Ruiz M et al.. “Effect of pulmonary artery catheter, type & combination of vasoactives for optimizing lactate clearance in acute myocardial infarction complicated by cardiogenic shock.” Journal of critical care (2025). PMID: 39667287 ↗

    L3OTHERCited in: Pharmacological Management: Inotropes and Vasopressors
  128. [128]

    Aissaoui N, Delmas C, Merdji H et al.. “Experts' recommendations for the management of adult patients with cardiogenic shock.” Archives of cardiovascular diseases (2026). PMID: 41876324 ↗

    L1GUIDELINECited in: Temporary Mechanical Circulatory Support (tMCS), Revascularization and Definitive Interventions, Guidelines and Management Algorithms
  129. [129]

    Papakonstantinou NA, Antonopoulos CN. “Extracorporeal Membrane Oxygenation Following Acute Type A Aortic Dissection Repair: A Systematic Review and Meta-Analysis.” ASAIO journal (American Society for Artificial Internal Organs : 1992) (2026). PMID: 41736226 ↗

    L2SR_OBSCited in: Temporary Mechanical Circulatory Support (tMCS)
  130. [130]

    Nolan GP, Hammond MC, Rahimov D et al.. “Valvular Complications Related to Microaxial Assist Device Use: A Case-Level Systematic Review.” Artificial organs (2026). PMID: 41410269 ↗

    L4SR_OBSCited in: Temporary Mechanical Circulatory Support (tMCS)
  131. [131]

    Peng S, Li Z, Wang S et al.. “Impact of left ventricular unloading timing on clinical outcomes in venoarterial extracorporeal membrane oxygenation: an updated systematic review and meta-analysis.” BMC cardiovascular disorders (2025). PMID: 41126042 ↗

    L2SR_OBSCited in: Temporary Mechanical Circulatory Support (tMCS), Prognostication and Long-term Outcomes
  132. [132]

    Grand J, Freund A, Møller JE. “Best of European Heart Journal-Acute Cardiovascular Care (2024-25): cardiogenic shock and mechanical circulatory support.” European heart journal. Acute cardiovascular care (2026). PMID: 41642688 ↗

    L5REVIEW_NARRATIVECited in: Temporary Mechanical Circulatory Support (tMCS)
  133. [133]

    Thiele H, Hassager C. “Cardiogenic Shock.” The New England journal of medicine (2026). PMID: 41467651 ↗

    L5REVIEW_NARRATIVECited in: Temporary Mechanical Circulatory Support (tMCS), Revascularization and Definitive Interventions
  134. [134]

    Alarfaj M, Mohamad Alahmad MA, Wallisch WJ et al.. “ELSO-score: A practical pre-ECMO risk model for predicting in-hospital mortality in patients receiving VA-ECMO.” International journal of cardiology (2026). PMID: 42097309 ↗

    L2OTHERCited in: Temporary Mechanical Circulatory Support (tMCS)
  135. [135]

    Lewin D, Nersesian G, Rojas SV et al.. “Impact of Partial- to Full-Support Escalation With Microaxial Flow Pumps Prior to Durable Left Ventricular Assist Device Implantation.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2026). PMID: 42087324 ↗

    L3OTHERCited in: Temporary Mechanical Circulatory Support (tMCS)
  136. [136]

    Dahiya G, Bohman JK, Tonna JE et al.. “Acid-Base Status During Venoarterial Extracorporeal Membrane Oxygenator Support in Patients With Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 41823232 ↗

    L3OTHERCited in: Temporary Mechanical Circulatory Support (tMCS)
  137. [137]

    Lio V, Barbero U, Drago S et al.. “Sheathless Femoral Impella Implantation: A Safer Hemodynamic Support in High-Risk PCI and Cardiogenic Shock.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41773429 ↗

    L4OTHERCited in: Temporary Mechanical Circulatory Support (tMCS), Revascularization and Definitive Interventions
  138. [138]

    Beurton A, Bordier E, Veyret S et al.. “Changes in hemodynamics, cardiac energetics, and cell signaling pathways induced by veno-arterial extracorporeal membrane oxygenation with or without left ventricular active unloading.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2026). PMID: 41667045 ↗

    L4OTHERCited in: Temporary Mechanical Circulatory Support (tMCS)
  139. [139]

    Walther CP, Nair AP. “Management of Dialysis for Patients Receiving Mechanical Circulatory Support.” Journal of the American Society of Nephrology : JASN (2026). PMID: 41563801 ↗

    L5OTHERCited in: Temporary Mechanical Circulatory Support (tMCS)
  140. [140]

    Anderson M, Zeeshan A, Katlaps GJ et al.. “Clinical outcomes in acute myocardial infarction cardiogenic shock patients supported with a high-flow, surgically implanted micro-axial flow pump.” The Journal of thoracic and cardiovascular surgery (2026). PMID: 41548842 ↗

    L2OTHERCited in: Temporary Mechanical Circulatory Support (tMCS)
  141. [141]

    Baldetti L, Pontillo D, Capoccia M et al.. “Venopulmonary extracorporeal life support: An Extracorporeal Life Support Organization registry analysis.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2026). PMID: 41506589 ↗

    L3OTHERCited in: Temporary Mechanical Circulatory Support (tMCS)
  142. [142]

    Ortuno S, Bachelet D, Varnet O et al.. “Long-Term Functional and Quality-of-Life Outcomes in Survivors of Refractory Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation.” Critical care explorations (2025). PMID: 41329803 ↗

    L3OTHERCited in: Temporary Mechanical Circulatory Support (tMCS)
  143. [143]

    Ahn DJ, White M, Ran G et al.. “Low rates of inotropic support and durable left ventricular assist device placement among status 2 heart transplant candidates with temporary mechanical circulatory support.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2026). PMID: 41241033 ↗

    L3OTHERCited in: Temporary Mechanical Circulatory Support (tMCS)
  144. [144]

    Zainab K, Taylor E, Gangasani N et al.. “Aortic Pulsatility Index Predicts Native Recovery in Patients With Cardiogenic Shock Supported by Intra-aortic Balloon Pumps.” Journal of cardiac failure (2025). PMID: 41233015 ↗

    L3OTHERCited in: Temporary Mechanical Circulatory Support (tMCS)
  145. [145]

    Marquard JM, Beske RP, Hassager C et al.. “Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.” JACC. Cardiovascular interventions (2025). PMID: 40992803 ↗

    L2RCTCited in: Revascularization and Definitive Interventions, Multiorgan Dysfunction and Supportive Care, Prognostication and Long-term Outcomes
  146. [146]

    Abumayyaleh M, Thiele H, Rassaf T et al.. “Femoral vs. radial approach for primary percutaneous intervention in cardiogenic shock: a subanalysis from the ECLS-SHOCK trial.” European heart journal. Acute cardiovascular care (2025). PMID: 40042826 ↗

    L2RCTCited in: Revascularization and Definitive Interventions
  147. [147]

    Kaczorowski DJ, Takeda K, Atluri P et al.. “2025 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Surgical management of acute myocardial infarction and associated complications.” The Journal of thoracic and cardiovascular surgery (2025). PMID: 40320004 ↗

    L1GUIDELINECited in: Revascularization and Definitive Interventions, Guidelines and Management Algorithms
  148. [148]

    Larik MO, Shaukat A, Khan M et al.. “Impact of Access Site in Percutaneous Coronary Intervention for Patients Complicated With Cardiogenic Shock: A Systematic Review and Meta-Analysis of 33,311 Individuals.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40827467 ↗

    L2SR_OBSCited in: Revascularization and Definitive Interventions, Prognostication and Long-term Outcomes
  149. [149]

    Mondellini GM, van den Enden AJM, Van Mieghem NM. “Perspectives on why DanGer Shock is the first positive trial on mechanical circulatory support in cardiogenic shock.” Heart failure reviews (2025). PMID: 39661305 ↗

    L5SR_OBSCited in: Revascularization and Definitive Interventions
  150. [150]

    Jung RG, Stotts C, Gupta A et al.. “Prognostic Factors Associated with Mortality in Cardiogenic Shock - A Systematic Review and Meta-Analysis.” NEJM evidence (2024). PMID: 39437131 ↗

    L2SR_OBSCited in: Revascularization and Definitive Interventions
  151. [151]

    D'Andria Ursoleo J, Baldetti L, Pieri M et al.. “Anti-Platelet Therapy with Cangrelor in Cardiogenic Shock Patients: A Systematic Review and Single-Arm Meta-Analysis.” Medicina (Kaunas, Lithuania) (2024). PMID: 39768971 ↗

    L2SR_OBSCited in: Revascularization and Definitive Interventions
  152. [152]

    Turner H, Townsend M, Strange J et al.. “Long-Term Survival After Post-Myocardial Infarction Ventricular Septal Defect (VSD) Closure, Multiple Percutaneous Coronary Interventions and Edge-to-Edge Repair.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40988354 ↗

    L4CASE_REPORTCited in: Revascularization and Definitive Interventions
  153. [153]

    Chandra Mohan N, Govier M, Johnson TW et al.. “Advanced Cardiogenic-shock Team versus standard care in cardiogenic SHOCK: a single centre service evaluation project.” Open heart (2026). PMID: 41577369 ↗

    L3OTHERCited in: Revascularization and Definitive Interventions
  154. [154]

    Vicent L, Salguero-Bodes R, Ynsaurriaga FA et al.. “Cardiogenic Shock; Health Disparities; Equity; Mechanical Circulatory Support; Sex Differences; Multidisciplinary Care; Protocolized Care.” Current heart failure reports (2025). PMID: 41258337 ↗

    L5REVIEW_NARRATIVECited in: Revascularization and Definitive Interventions
  155. [155]

    An KR, Harik L, Rahouma M et al.. “Trends and Outcomes of Mechanical Circulatory Support in Acute Myocardial Infarction and Cardiogenic Shock Patients Undergoing Coronary Artery Bypass Grafting.” The Annals of thoracic surgery (2026). PMID: 41109582 ↗

    L2OTHERCited in: Revascularization and Definitive Interventions
  156. [156]

    Planka RM, Herold L, Glantschnig T et al.. “Applying DanGer Shock Eligibility Criteria to a Real-World Cohort of Cardiogenic Shock Patients.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 41077835 ↗

    L3OTHERCited in: Revascularization and Definitive Interventions
  157. [157]

    Ko T, Hosokawa Y, Asai K et al.. “Contribution of First Contact With a Cardiologist to the Door-to-Cardiac Catheterization Laboratory Time in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock　- Data From K-ACTIVE.” Circulation journal : official journal of the Japanese Circulation Society (2025). PMID: 40976693 ↗

    L3OTHERCited in: Revascularization and Definitive Interventions
  158. [158]

    Patel R, Ghanem F, Rafique S et al.. “Outcomes of Culprit-Only Versus Multi-Vessel PCI With Impella Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40947547 ↗

    L2OTHERCited in: Revascularization and Definitive Interventions
  159. [159]

    Eastwood GM, Bailey M, Nichol AD et al.. “Impact of mild hypercapnia on renal function after out-of-hospital cardiac arrest.” Resuscitation (2025). PMID: 39742940 ↗

    L1RCTCited in: Multiorgan Dysfunction and Supportive Care
  160. [160]

    Zweck E, Hassager C, Beske RP et al.. “Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial.” Circulation (2024). PMID: 39462276 ↗

    L1RCTCited in: Multiorgan Dysfunction and Supportive Care, Landmark Trials and Evidence-Based Evolution
  161. [161]

    Ostadal P, Rokyta R, Karasek J et al.. “Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: 1-year outcomes of the multicentre, randomized ECMO-CS trial.” European journal of heart failure (2025). PMID: 39113628 ↗

    L1RCTCited in: Multiorgan Dysfunction and Supportive Care
  162. [162]

    Ott S, Dresen E, Lee ZY et al.. “The effect of high-dose selenium on mortality and postoperative organ dysfunction in post-cardiotomy cardiogenic shock patients supported with mechanical circulatory support - A post-hoc analysis of the SUSTAIN CSX trial.” Journal of critical care (2024). PMID: 38955117 ↗

    L2RCTCited in: Multiorgan Dysfunction and Supportive Care
  163. [163]

    Levy B, Girerd N, Amour J et al.. “Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial.” JAMA (2022). PMID: 35103766 ↗

    L1RCTCited in: Multiorgan Dysfunction and Supportive Care
  164. [164]

    Lim O, Anbalakan K, Ruiyang Ling R et al.. “Concurrent Use of Kidney Replacement Therapy and Temporary Left Ventricular Assist Device in Cardiogenic Shock: A Systematic Review and Meta-Analysis.” Blood purification (2025). PMID: 40532684 ↗

    L2SR_OBSCited in: Multiorgan Dysfunction and Supportive Care
  165. [165]

    Karamat M, Patel B, Khanal R et al.. “Sex-related differences in patients with acute myocardial infarction complicated by cardiogenic shock: A systematic review and meta-analysis.” The American journal of the medical sciences (2025). PMID: 39647638 ↗

    L2SR_OBSCited in: Multiorgan Dysfunction and Supportive Care
  166. [166]

    Lescroart M, Kemp H, Imauven O et al.. “Cardiogenic shock in patients with active onco-hematological malignancies: A multicenter retrospective study.” Journal of critical care (2025). PMID: 39848115 ↗

    L3COHORTCited in: Multiorgan Dysfunction and Supportive Care
  167. [167]

    Sitbon A, Coutrot M, Montero S et al.. “Early renal recovery after acute kidney injury in patients on venoarterial extracorporeal membrane oxygenation: A retrospective study.” Journal of critical care (2023). PMID: 37540960 ↗

    L3COHORTCited in: Multiorgan Dysfunction and Supportive Care
  168. [168]

    De Oliveira-Gomes D, Guilliod C, Vavilin I et al.. “Renal Dysfunction Across the Spectrum of Cardiogenic Shock: Mechanisms, Clinical Implications, and Therapeutic Strategies.” Current heart failure reports (2025). PMID: 40560292 ↗

    L5REVIEW_NARRATIVECited in: Multiorgan Dysfunction and Supportive Care
  169. [169]

    Sarma D, Jentzer JC. “Cardiogenic Shock: Pathogenesis, Classification, and Management.” Critical care clinics (2024). PMID: 37973356 ↗

    L5REVIEW_NARRATIVECited in: Multiorgan Dysfunction and Supportive Care
  170. [170]

    Tavazzi G. “Mechanical ventilation in cardiogenic shock.” Current opinion in critical care (2021). PMID: 33929345 ↗

    L5REVIEW_NARRATIVECited in: Multiorgan Dysfunction and Supportive Care
  171. [171]

    Rubini Gimenez M, Zeymer U, Desch S et al.. “Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock: A Substudy of the CULPRIT-SHOCK Trial.” Circulation. Cardiovascular interventions (2020). PMID: 32151161 ↗

    L1RCTCited in: Landmark Trials and Evidence-Based Evolution
  172. [172]

    Henry TD, Tomey MI, Tamis-Holland JE et al.. “Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Scientific Statement From the American Heart Association.” Circulation (2021). PMID: 33657830 ↗

    L1REVIEW_NARRATIVECited in: Landmark Trials and Evidence-Based Evolution
  173. [173]

    Lüsebrink E, Binzenhöfer L, Hering D et al.. “Scrutinizing the Role of Venoarterial Extracorporeal Membrane Oxygenation: Has Clinical Practice Outpaced the Evidence?” Circulation (2024). PMID: 38527130 ↗

    L5REVIEW_NARRATIVECited in: Landmark Trials and Evidence-Based Evolution
  174. [174]

    Schrage B, Ibrahim K, Loehn T et al.. “Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock.” Circulation (2019). PMID: 30586755 ↗

    L3OTHERCited in: Landmark Trials and Evidence-Based Evolution
  175. [175]

    Basir MB, Kapur NK, Patel K et al.. “Improved Outcomes Associated with the use of Shock Protocols: Updates from the National Cardiogenic Shock Initiative.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019). PMID: 31025538 ↗

    L2OTHERCited in: Landmark Trials and Evidence-Based Evolution
  176. [176]

    Dimitriadis K, Pyrpyris N, Aznaouridis K et al.. “Direct Comparison of Urgent Transcatheter Aortic Valve Implantation and Balloon Aortic Valvuloplasty: A Systematic Review and Meta-Analysis.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40988363 ↗

    L2SR_OBSCited in: Prognostication and Long-term Outcomes
  177. [177]

    Soh BWT, Gracias CS, Dean A et al.. “A Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Mechanical Circulatory Support in Acute Myocardial Infarction Related Cardiogenic Shock.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 39718168 ↗

    L2SR_OBSCited in: Prognostication and Long-term Outcomes
  178. [178]

    Schupp T, Thiele H, Rassaf T et al.. “Prognostic Impact of Admission Time in Infarct-Related Cardiogenic Shock: An ECLS-SHOCK Substudy.” JACC. Cardiovascular interventions (2024). PMID: 39415381 ↗

    L2RCTCited in: Prognostication and Long-term Outcomes
  179. [179]

    Ahmed A, Contreras R, Gurram A et al.. “Clinical outcomes of transcatheter edge-to-edge repair in patients with acute mitral regurgitation complicated by cardiogenic shock: a systematic review and meta-analysis.” BMC cardiovascular disorders (2025). PMID: 40389818 ↗

    L2SR_OBSCited in: Prognostication and Long-term Outcomes
  180. [180]

    Zordok M, Buda KG, Etiwy M et al.. “Comparative analysis of the DanGer Shock trial to randomized cardiogenic shock trials and real-world registries.” Cardiovascular revascularization medicine : including molecular interventions (2025). PMID: 39890500 ↗

    L1SR_OBSCited in: Prognostication and Long-term Outcomes
  181. [181]

    Xie L, Luo S. “Prognostic value of glycaemic variability for mortality in cardiogenic shock patients: a retrospective cohort study.” Cardiovascular diabetology (2025). PMID: 41074054 ↗

    L3COHORTCited in: Prognostication and Long-term Outcomes
  182. [182]

    Mudrovcic N, Tegnesjö E, Green RW et al.. “Clinical Features of Myocardial Infarction in Women With a History of Preeclampsia: A Population-Based Cohort Study.” Circulation. Cardiovascular quality and outcomes (2025). PMID: 40151932 ↗

    L2COHORTCited in: Prognostication and Long-term Outcomes
  183. [183]

    Shen C, Wang S, Huo R et al.. “Comparison of machine learning and nomogram to predict 30-day in-hospital mortality in patients with acute myocardial infarction combined with cardiogenic shock: a retrospective study based on the eICU-CRD and MIMIC-IV databases.” BMC cardiovascular disorders (2025). PMID: 40108540 ↗

    L3COHORTCited in: Prognostication and Long-term Outcomes
  184. [184]

    Mumbulu ET, Nkodila AN, Saint-Joy V et al.. “Survival and predictors of mortality in patients with heart failure in the cardiology department of the Center Hospitalier Basse Terre in Guadeloupe: historical cohort study.” BMC cardiovascular disorders (2024). PMID: 39468485 ↗

    L3COHORTCited in: Prognostication and Long-term Outcomes
  185. [185]

    Baron SJ, Chou JC, Shah T et al.. “SCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women.” EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (2025). PMID: 40387531 ↗

    L5GUIDELINECited in: Guidelines and Management Algorithms
  186. [186]

    Grant MC, Kanwar MK, Spelde AE et al.. “Temporary Mechanical Circulatory Support in Cardiogenic Shock: Executive Summary of the Joint Consensus Reports of the PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society.” The Annals of thoracic surgery (2025). PMID: 40185355 ↗

    L1GUIDELINECited in: Guidelines and Management Algorithms
  187. [187]

    Spelde AE, Barron LM, Cangut B et al.. “Escalation and De-escalation of Temporary Mechanical Circulatory Support: Joint Consensus Report of the PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society.” The Annals of thoracic surgery (2025). PMID: 40187586 ↗

    L1GUIDELINECited in: Guidelines and Management Algorithms
  188. [188]

    Kalla K, Christ G, Karnik R et al.. “Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry).” Circulation (2006). PMID: 16702474 ↗

    L2GUIDELINECited in: Guidelines and Management Algorithms
  189. [189]

    Pilarczyk K, Werdan K, Russ M et al.. “The German-Austrian S3 Guideline "Cardiogenic Shock Due to Myocardial Infarction: Diagnosis, Monitoring, and Treatment".” The Thoracic and cardiovascular surgeon (2021). PMID: 33368106 ↗

    L1GUIDELINECited in: Guidelines and Management Algorithms
  190. [190]

    Hermes C, Ochmann T, Keienburg C et al.. “[Intensive care of patients with [infarct-related] cardiogenic shock : Abridged version of the S1 guideline].” Medizinische Klinik, Intensivmedizin und Notfallmedizin (2022). PMID: 36040499 ↗

    L5GUIDELINECited in: Guidelines and Management Algorithms
  191. [191]

    Bonello L, Delmas C, Schurtz G et al.. “Mechanical circulatory support in patients with cardiogenic shock in intensive care units: A position paper of the "Unité de Soins Intensifs de Cardiologie" group of the French Society of Cardiology, endorsed by the "Groupe Athérome et Cardiologie Interventionnelle" of the French Society of Cardiology.” Archives of cardiovascular diseases (2018). PMID: 29903693 ↗

    L5GUIDELINECited in: Guidelines and Management Algorithms

Revision History

All updates applied to this page

Loading revisions…